These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3006459)

  • 1. Biochemical mechanisms in 5-hydroxytryptamine-induced human platelet aggregation.
    de Clerck F; Xhonneux B; van de Wiele R
    Agents Actions; 1985 Dec; 17(2):220-8. PubMed ID: 3006459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization.
    Lanza F; Beretz A; Stierlé A; Corre G; Cazenave JP
    Thromb Res; 1987 Mar; 45(5):477-84. PubMed ID: 3035738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
    Patscheke H; Stegmeier K
    Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ca2+ as messenger of 5HT2-receptor stimulation in human blood platelets.
    Affolter H; Erne P; Bürgisser E; Pletscher A
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Apr; 325(4):337-42. PubMed ID: 6427633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.
    Minkes M; Stanford N; Chi MM; Roth GJ; Raz A; Needleman P; Majerus PW
    J Clin Invest; 1977 Mar; 59(3):449-54. PubMed ID: 190267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of cyclic nucleotides in platelet function.
    Haslam RJ
    Ciba Found Symp; 1975; 35():121-51. PubMed ID: 179765
    [No Abstract]   [Full Text] [Related]  

  • 9. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrelationships between Ca2+ and adenylate and guanylate cyclases in the control of platelet secretion and aggregation.
    Rodan GA; Feinstein MB
    Proc Natl Acad Sci U S A; 1976 Jun; 73(6):1829-33. PubMed ID: 6960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biphasic effect on platelet aggregation by phospholipase a purified from Vipera russellii snake venom.
    Teng CM; Chen YH; Ouyang C
    Biochim Biophys Acta; 1984 May; 772(3):393-402. PubMed ID: 6426517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of platelet adenylate cyclase by ADP.
    Mellwig KP; Jakobs KH
    Thromb Res; 1980 Apr 1-15; 18(1-2):7-17. PubMed ID: 6250246
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxytryptamine and the metabolism of arachidonic acid by the lipoxygenase and cyclooxygenase of washed human platelets.
    Dragan YP; Ellis EF
    Biochem Pharmacol; 1990 Jul; 40(2):309-14. PubMed ID: 2142882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and dazoxiben as inhibitors of platelet behaviour: modification of their effects by agents that alter cAMP production.
    Sills T; Cowley AJ; Heptinstall S
    Thromb Res; 1986 Apr; 42(1):91-8. PubMed ID: 3010495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disaggregation and reaggregation of 'irreversibly' aggregated platelets: a method for more complete evaluation of anti-platelet drugs.
    Rao GH; White JG
    Agents Actions; 1985 Jul; 16(5):425-34. PubMed ID: 3931443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High concentrations of exogenous arachidonate inhibit calcium mobilization in platelets by stimulation of adenylate cyclase.
    Kowalska MA; Rao AK; Disa J
    Biochem J; 1988 Jul; 253(1):255-62. PubMed ID: 2458717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AMP.
    Feinstein MB; Fraser C
    J Gen Physiol; 1975 Nov; 66(5):561-81. PubMed ID: 172596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.